Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03784898 · ClinicalTrials.gov registry record · Phase 4
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
A Phase 4 study of Multiple Sclerosis, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03784898: Completed Phase 4 study of Multiple Sclerosis, sponsored by Genzyme, a Sanofi Company.
NCT03784898 is a Phase 4 study of Multiple Sclerosis that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 13 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03784898, a Phase 4 study of Multiple Sclerosis, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic acid (DNA) analysis as part of a global biomarker project assessing pre-identified candidate single nucleotide polymorphisms (SNPs) associated to the development of ITP after LEMTRADA treatment in RMS participants.
Primary Outcome
Each participant provided a maximum total of 69 milliliter of whole blood sample. Samples were collected in the following order: 1. Deoxyribonucleic acid (DNA) Paired box (PAX)gene tubes (2 tubes), 2. Ribonucleic acid (RNA) PAXgene tubes (2 tubes), 3. Ethylenediaminetetraacetic acid (EDTA) tubes for peripheral blood mononuclear cells (PBMCs) (5 tubes), 4. Serum Separator tube (SST) (1 tube), and 5. Dipotassium Ethylenediaminetetraacetic acid (K2EDTA) tube (1 tube); where DNA PAXgene tubes were u
Conditions Studied
Interventions
- OTHER Blood draw for future biomarker analysis
Study Locations (1)
California
- Investigational Site Number 8400001 - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-02-08 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 4 |
What the finished NCT03784898 record still lists
NCT03784898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Blood draw for future biomarker analysis is the first listed.
NCT03784898 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03784898 about?
NCT03784898 is a clinical study titled "Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada". Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic acid (DNA) analysis as part of a global biomarker project assessing p...
What is the current status of trial NCT03784898?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2019-02-08. Estimated completion is 2019-12-11.
What conditions does trial NCT03784898 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT03784898?
The interventions under investigation include: Blood draw for future biomarker analysis (OTHER).
Who is sponsoring clinical trial NCT03784898?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03784898 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03784898's enrollment target sits among peer trials
13 294th of 315 higher than 20 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 4
-
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Glucose Consumption in MS Using [F-18]FDG-PET
RECRUITING · Phase 4
-
Home Based Infusions for Ocrelizumab
RECRUITING · Phase 4
-
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI